First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

PHASE3CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

June 15, 2022

Study Completion Date

June 24, 2022

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Panitumumab

6 mg/kg iv over 60 minutes, day 1

DRUG

Irinotecan

150 mg/sqm iv over 60 minutes day 1

DRUG

Oxaliplatin

85 mg/sqm iv over 2 hours day 1

DRUG

l-leucovorin

200 mg/sqm iv over 2 hours

DRUG

5-fluorouracil

400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;

Trial Locations (4)

20133

Fondazione IRCCS Istituto Nazionale Tumori, Milan

35128

Fondazione IRCCS Istituto Oncologico Veneto, Padua

37126

Azienda Ospedaliera Universitaria Integrata Verona, Verona

56126

A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica, Pisa

All Listed Sponsors
lead

Gruppo Oncologico del Nord-Ovest

OTHER

NCT03231722 - First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS | Biotech Hunter | Biotech Hunter